Science News: Clinical Science Special Reports

Scientific Sessions 2017

Scientific Sessions: November 11–15

Resuscitation Science Symposium: November 11–13

Cardiovascular Nursing Clinical Symposium: November 13–14

Anaheim, California

CSSR.03 - Risk Reduction Strategies on a Global Stage

Monday, Nov. 14 | 9:00 a.m. - 10:15 a.m. |  Main Event 2
Risk Reduction Strategies on a Global Stage

Sid Smith, MD, past president of the American Heart Association, Mark Huffman, MD, MPH, and Donald Lloyd-Jones, MD discuss some recent global risk reduction strategy initiatives that were presented during Scientific Sessions 2016. The discussion relates to studies presented at 9:00 a.m.  Monday morning.

A Comprehensive Lifestyle Intervention in Patients With Coronary Artery Disease: Main Results of the Randomized Multicenter Response 2 Trial
J Ron Peters | Academic Medical Center, Amsterdam, Netherlands

RESULTS: Referral of patients with CAD to a comprehensive set of community-based lifestyle interventions (weight reduction, improved physical activity, and smoking cessation) on top of usual care led to 38% relative improvement.

A Cluster Randomized Trial of a Comprehensive Approach for Hypertension Control in Low-income Patients in Argentina
Jiang He | Tulane University, New Orleans, LA

RESULTS: Systolic and diastolic BP was reduced, medication adherence, and the proportion of controlled hypertension was increased in the study group using this intervention approach.

A Randomized Trial of Community Health Action to Encourage healthy Behaviors: The Grenada Heart Project -CHANGE Trial
Sameer Bansilal | Icahn School of Medicine at Mount Sinai, New York, NY

RESULTS: Peer group support in this low resource setting improved behaviors for people at cardiovascular risk.

Large Scale Analysis of Lifetime Risk of Cardiovascular Disease in Europe and Population Attributable Risk of Cardiovascular Risk Factors for the Biomarkers for Cardiovascular Risk Assessment in Europe (BiomarCaRE) Investigators
Stefan Blankenberg | University Heart Center Hamburg, Hamburg, Germany

RESULTS: Diabetes, smoking, and hypertension had the highest population attributable risks; cholesterol and BMI followed these. All of the risk factors were associated to incident cardiovascular disease.

CSSR.01 - Cell Therapy: Ready for Prime Time?

Monday, Nov. 14 | 3:45 p.m. - 5:00 p.m. | Main Event 2
Michael P. Murphy

Administration of Autologous Bone Marrow Cells for Limb Salvage in Patients With Critical Limb Ischemia: Results of the Multicenter Phase III MOBILE Trial
Michael P Murphy | Indiana University School of Medicine, Indianapolis, IN

RESULTS: Administration of autologous bone marrow cells for limb salvage in patients with critical limb ischemia improved amputation free survival in non-diabetic patients.

Emerson C. Perin

Administration of ALDH Bright Cells to Patients With Intermittent Claudication: The NHLBI CCTRN PACE Trial
Emerson C. Perin, | Texas Heart Institute, Houston, TX

RESULTS: Administration of ALDH Bright Cells to patients with intermittent claudication did not change by 6 months for the primary endpoints, peak walking time, collateral count, peak hyperemic popliteal flow, or capillary perfusion.

Joshua M Hare

Randomized Comparison of Allogeneic vs Autologous Mesenchymal Stem Cells in Patients With Non-Ischemic Dilated Cardiomyopathy - The POSEIDON-DCM Trial
Joshua M Hare | University of Miami, Miami, FL

RESULTS: A comparison of allogeneic vs autologous mesenchymal stem cells in patients with non-ischemic dilated cardiomyopathy followed for 12 months demonstrated safety and greater clinical efficacy (no 30-day serious adverse events for both, less 12-month SAE’s for allogeneic vs. autologous, and for allogeneic: no immune rejection, increased ejection fraction, increased 6-minute walk test, and lower MACE and hospitalizations).

Jay H Traverse

The NHLBI TIME Trial: Role of Microvascular Obstruction in 2-Year Clinical and MRI Follow-up
Jay H Traverse| Minneapolis Heart Institute Foundation Abbott Northwestern Hospital, Minneapolis, MN

RESULTS: The long-term (2-year) effects of microvascular obstruction (evaluated by cardiac MRI) suggest a worse prognosis for recovery of left ventricular function and MACE in this patient population who received intracoronary autologous bone marrow mononuclear cells after STEMI.

CSSR.04 - Hi Impact EP Registries and Clinical Trials

Tuesday, Nov. 15 | 10:45 a.m. - 12:00 p.m. | Room 260-262

Atrial Substrate Modification With Aggressive Blood Pressure Control to Prevent Atrial Fibrillation (SMAC AF)
Ratika Parkash | QEII Health Sciences Center, Halifax, NS, Canada

RESULTS: The recurrence of AF after ablation was decreased with aggressive blood pressure control before and after catheter ablation for AF.

Prevalence of Sub-Clinical Atrial Fibrillation Using an Implantable Cardiac Monitor in Patients With Cardiovascular Risk Factors: ASSERT II
Jeff S Healey | McMaster University, Hamilton, ON, Canada

RESULTS: Sub-clinical AF was found to be common in patients 65 years and older patients with cardiovascular risk factors.

The San Francisco POstmortem Systematic InvesTigation of Sudden Cardiac Death (POST SCD) Study
Zian H Tseng | UC San Francisco, San Francisco, CA

RESULTS: Based on autopsy findings, 56% of out of hospital deaths were true sudden cardiac deaths.

Idarucizumab For Dabigatran Reversal: Updated Results Of The Re-verse Ad Study
Charles V Pollack | Thomas Jefferson University, Philadelphia, PA

RESULTS: The anticoagulant effect of dabigatran was quickly and safely reversed with idarucizumab.

CSSR.02 - Precision Medicine on the Front Lines

Tuesday, Nov. 15 | 3:45 p.m. - 5:00 p.m. | Main Event 2

A Genome-wide Association Study (GWAS) Identifies Novel Loci Associated With Clinically Defined Statin-Associated Muscle Symptoms in a Double-Blind Cross-Over Re-challenge Trial
Erik Stroes | Academic Medical Center, Amsterdam, Netherlands

RESULTS: The Genome-wide Association Study (GWAS) identified several novel, genome-wide significant associations associated with clinically defined satin-associated muscle symptoms.

Incidence of Acute Myocardial Infarction in Patients With Genotyped Familial Hypercholesterolemia in Norway During 2001-2009
Kjetil Retterstøl, University of Oslo and Oslo University Hospital, Oslo, Norway

RESULTS: In this Norwegian population with genetically verified FH, a significantly higher incidence of acute myocardial infarction was seen, especially in the younger age groups (25-39). In men 40-49, cerebrovascular disease was also significantly increased.

A Loss-of-Function Variant in CETP Is Associated With Altered Lipid Metabolism but Not With Cardiovascular Disease Incidence in Chinese Adults
Zhengming Chen | University of Oxford, Oxford, United Kingdom

RESULTS: A Loss-of-Function Variant in CETP was associated with altered HDL Metabolism but not with cardiovascular disease risk.

Prospective Clinical Implementation of CYP2C19-Genotype Guided Antiplatelet Therapy After PCI: a Multi-Site Investigation of MACE Outcomes in a Real-World Setting
Larisa H Cavallari | University of Florida, Gainesville, FL

RESULTS: MACE was decreased using CYP2C19 to guide antiplatelet therapy after PCI compared to continuing clopidogrel treatment.